Coronavirus Vaccine - Global Market Outlook (2018-2027)
According to Stratistics MRC, the Global Coronavirus Vaccine Market is accounted for $18.69 million in 2018 and is expected to reach $900.14 million by 2027 growing at a CAGR of 53.8% during the forecast period. The increasing prevalence of virus infected people across the world is anticipated to drive the growth of the market. However, factors such as high cost involved in research and development of therapeutic vaccines and drugs, and time required for each stage of clinical trials are hampering the market growth.
Corona viruses are a group of viruses which cause diseases or infections in mammals as well as birds. Coronaviruses belong to the Coronaviridae or Torovirinae subfamily. Symptoms caused by these viruses include common cold to serious infections, pneumonia, strict respiratory complications, even kidney failure, and death. These symptoms are common among persons with a weak immune system, individuals with cardiopulmonary disease, infants, and elderly people.
Based on the vaccine type, the DNA-based vaccine segment is going to have a lucrative growth during the forecast period the technological advancements in the field of pharmaceutical industry have resulted in development of various effective type of vaccines such as DNA-based nucleic acid vaccines. The use of these vaccines on human body leads to development of anti-gen. Thus, the effectiveness of the vaccine against the virus is enhanced significantly.
By geography, Europe is likely to have a huge demand due to diverse coronavirus outbreaks in the current past and presence of major players in countries in the region. As well, rising investments in R&D activities, along with strong support from the government is driving the growth of the target market in this region.
Some of the key players profiled in the Coronavirus Vaccine Market include Inovio Pharmaceuticals, Inc., Moderna, Inc., Protein Potential, LLC, Novavax, Inc., Synairgen PLC, AlphaVax, Inc., NanoViricides, Inc., Zydus Cadila, Bravovax, GeoVax, Altimmune, Janssen Pharmaceutical Companies, CanSino Biologics, Vaxart and Vaxil Bio Ltd.
Infection Types Covered:
• HCoV-229E
• HCoV-OC43
• HKU1-CoV
• MERS-CoV
• New Haven CoV
• SARS-CoV
Vaccine Types Covered:
• S-Protein Based Coronavirus Vaccine
• Live Attenuated Coronavirus Vaccine
• Inactivated Coronavirus Vaccine
• mRNA Vaccine
• DNA-Based Vaccine
Product Types Covered:
• Monovalent Vaccine
• Multivariant Vaccine
Route of Administrations Covered:
• Subcutaneous
• Oral
• Intramuscular
Patient Types Covered:
• Pediatric
• Adult
End Users Covered:
• Clinics
• Hospitals
• Research Institutes
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2017, 2018, 2019, 2023 and 2027
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Coronavirus Vaccine Market, By Infection Type
5.1 Introduction
5.2 HCoV-229E
5.3 HCoV-OC43
5.4 HKU1-CoV
5.5 MERS-CoV
5.6 New Haven CoV
5.7 SARS-CoV
6 Global Coronavirus Vaccine Market, By Vaccine Type
6.1 Introduction
6.2 S-Protein Based Coronavirus Vaccine
6.3 Live Attenuated Coronavirus Vaccine
6.4 Inactivated Coronavirus Vaccine
6.5 mRNA Vaccine
6.6 DNA-Based Vaccine
7 Global Coronavirus Vaccine Market, By Product Type
7.1 Introduction
7.2 Monovalent Vaccine
7.3 Multivariant Vaccine
8 Global Coronavirus Vaccine Market, By Route of Administration
8.1 Introduction
8.2 Subcutaneous
8.3 Oral
8.4 Intramuscular
9 Global Coronavirus Vaccine Market, By Patient Type
9.1 Introduction
9.2 Pediatric
9.3 Adult
10 Global Coronavirus Vaccine Market, By End User
10.1 Introduction
10.2 Clinics
10.3 Hospitals
10.4 Research Institutes
11 Global Coronavirus Vaccine Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 New Zealand
11.4.6 South Korea
11.4.7 Rest of Asia Pacific
11.5 South America
11.5.1 Argentina
11.5.2 Brazil
11.5.3 Chile
11.5.4 Rest of South America
11.6 Middle East & Africa
11.6.1 Saudi Arabia
11.6.2 UAE
11.6.3 Qatar
11.6.4 South Africa
11.6.5 Rest of Middle East & Africa
12 Key Developments
12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.4 Expansions
12.5 Other Key Strategies
13 Company Profiling
13.1 Inovio Pharmaceuticals, Inc.
13.2 Moderna, Inc.
13.3 Protein Potential, LLC
13.4 Novavax, Inc.
13.5 Synairgen PLC
13.6 AlphaVax, Inc.
13.7 NanoViricides, Inc.
13.8 Zydus Cadila
13.9 Bravovax
13.10 GeoVax
13.11 Altimmune
13.12 Janssen Pharmaceutical Companies
13.13 CanSino Biologics
13.14 Vaxart
13.15 Vaxil Bio Ltd
List of Tables
1 Global Coronavirus Vaccine Market Outlook, By Region (2017-2027) ($MN)
2 Global Coronavirus Vaccine Market Outlook, By Infection Type (2017-2027) ($MN)
3 Global Coronavirus Vaccine Market Outlook, By HCoV-229E (2017-2027) ($MN)
4 Global Coronavirus Vaccine Market Outlook, By HCoV-OC43 (2017-2027) ($MN)
5 Global Coronavirus Vaccine Market Outlook, By HKU1-CoV (2017-2027) ($MN)
6 Global Coronavirus Vaccine Market Outlook, By MERS-CoV (2017-2027) ($MN)
7 Global Coronavirus Vaccine Market Outlook, By New Haven CoV (2017-2027) ($MN)
8 Global Coronavirus Vaccine Market Outlook, By SARS-CoV (2017-2027) ($MN)
9 Global Coronavirus Vaccine Market Outlook, By Vaccine Type (2017-2027) ($MN)
10 Global Coronavirus Vaccine Market Outlook, By S-Protein Based Coronavirus Vaccine (2017-2027) ($MN)
11 Global Coronavirus Vaccine Market Outlook, By Live Attenuated Coronavirus Vaccine (2017-2027) ($MN)
12 Global Coronavirus Vaccine Market Outlook, By Inactivated Coronavirus Vaccine (2017-2027) ($MN)
13 Global Coronavirus Vaccine Market Outlook, By mRNA Vaccine (2017-2027) ($MN)
14 Global Coronavirus Vaccine Market Outlook, By DNA-Based Vaccine (2017-2027) ($MN)
15 Global Coronavirus Vaccine Market Outlook, By Product Type (2017-2027) ($MN)
16 Global Coronavirus Vaccine Market Outlook, By Monovalent Vaccine (2017-2027) ($MN)
17 Global Coronavirus Vaccine Market Outlook, By Multivariant Vaccine (2017-2027) ($MN)
18 Global Coronavirus Vaccine Market Outlook, By Route of Administration (2017-2027) ($MN)
19 Global Coronavirus Vaccine Market Outlook, By Subcutaneous (2017-2027) ($MN)
20 Global Coronavirus Vaccine Market Outlook, By Oral (2017-2027) ($MN)
21 Global Coronavirus Vaccine Market Outlook, By Intramuscular (2017-2027) ($MN)
22 Global Coronavirus Vaccine Market Outlook, By Patient Type (2017-2027) ($MN)
23 Global Coronavirus Vaccine Market Outlook, By Pediatric (2017-2027) ($MN)
24 Global Coronavirus Vaccine Market Outlook, By Adult (2017-2027) ($MN)
25 Global Coronavirus Vaccine Market Outlook, By End User (2017-2027) ($MN)
26 Global Coronavirus Vaccine Market Outlook, By Clinics (2017-2027) ($MN)
27 Global Coronavirus Vaccine Market Outlook, By Hospitals (2017-2027) ($MN)
28 Global Coronavirus Vaccine Market Outlook, By Research Institutes (2017-2027) ($MN)
29 North America Coronavirus Vaccine Market Outlook, By Country (2017-2027) ($MN)
30 North America Coronavirus Vaccine Market Outlook, By Infection Type (2017-2027) ($MN)
31 North America Coronavirus Vaccine Market Outlook, By HCoV-229E (2017-2027) ($MN)
32 North America Coronavirus Vaccine Market Outlook, By HCoV-OC43 (2017-2027) ($MN)
33 North America Coronavirus Vaccine Market Outlook, By HKU1-CoV (2017-2027) ($MN)
34 North America Coronavirus Vaccine Market Outlook, By MERS-CoV (2017-2027) ($MN)
35 North America Coronavirus Vaccine Market Outlook, By New Haven CoV (2017-2027) ($MN)
36 North America Coronavirus Vaccine Market Outlook, By SARS-CoV (2017-2027) ($MN)
37 North America Coronavirus Vaccine Market Outlook, By Vaccine Type (2017-2027) ($MN)
38 North America Coronavirus Vaccine Market Outlook, By S-Protein Based Coronavirus Vaccine (2017-2027) ($MN)
39 North America Coronavirus Vaccine Market Outlook, By Live Attenuated Coronavirus Vaccine (2017-2027) ($MN)
40 North America Coronavirus Vaccine Market Outlook, By Inactivated Coronavirus Vaccine (2017-2027) ($MN)
41 North America Coronavirus Vaccine Market Outlook, By mRNA Vaccine (2017-2027) ($MN)
42 North America Coronavirus Vaccine Market Outlook, By DNA-Based Vaccine (2017-2027) ($MN)
43 North America Coronavirus Vaccine Market Outlook, By Product Type (2017-2027) ($MN)
44 North America Coronavirus Vaccine Market Outlook, By Monovalent Vaccine (2017-2027) ($MN)
45 North America Coronavirus Vaccine Market Outlook, By Multivariant Vaccine (2017-2027) ($MN)
46 North America Coronavirus Vaccine Market Outlook, By Route of Administration (2017-2027) ($MN)
47 North America Coronavirus Vaccine Market Outlook, By Subcutaneous (2017-2027) ($MN)
48 North America Coronavirus Vaccine Market Outlook, By Oral (2017-2027) ($MN)
49 North America Coronavirus Vaccine Market Outlook, By Intramuscular (2017-2027) ($MN)
50 North America Coronavirus Vaccine Market Outlook, By Patient Type (2017-2027) ($MN)
51 North America Coronavirus Vaccine Market Outlook, By Pediatric (2017-2027) ($MN)
52 North America Coronavirus Vaccine Market Outlook, By Adult (2017-2027) ($MN)
53 North America Coronavirus Vaccine Market Outlook, By End User (2017-2027) ($MN)
54 North America Coronavirus Vaccine Market Outlook, By Clinics (2017-2027) ($MN)
55 North America Coronavirus Vaccine Market Outlook, By Hospitals (2017-2027) ($MN)
56 North America Coronavirus Vaccine Market Outlook, By Research Institutes (2017-2027) ($MN)
57 Europe Coronavirus Vaccine Market Outlook, By Country (2017-2027) ($MN)
58 Europe Coronavirus Vaccine Market Outlook, By Infection Type (2017-2027) ($MN)
59 Europe Coronavirus Vaccine Market Outlook, By HCoV-229E (2017-2027) ($MN)
60 Europe Coronavirus Vaccine Market Outlook, By HCoV-OC43 (2017-2027) ($MN)
61 Europe Coronavirus Vaccine Market Outlook, By HKU1-CoV (2017-2027) ($MN)
62 Europe Coronavirus Vaccine Market Outlook, By MERS-CoV (2017-2027) ($MN)
63 Europe Coronavirus Vaccine Market Outlook, By New Haven CoV (2017-2027) ($MN)
64 Europe Coronavirus Vaccine Market Outlook, By SARS-CoV (2017-2027) ($MN)
65 Europe Coronavirus Vaccine Market Outlook, By Vaccine Type (2017-2027) ($MN)
66 Europe Coronavirus Vaccine Market Outlook, By S-Protein Based Coronavirus Vaccine (2017-2027) ($MN)
67 Europe Coronavirus Vaccine Market Outlook, By Live Attenuated Coronavirus Vaccine (2017-2027) ($MN)
68 Europe Coronavirus Vaccine Market Outlook, By Inactivated Coronavirus Vaccine (2017-2027) ($MN)
69 Europe Coronavirus Vaccine Market Outlook, By mRNA Vaccine (2017-2027) ($MN)
70 Europe Coronavirus Vaccine Market Outlook, By DNA-Based Vaccine (2017-2027) ($MN)
71 Europe Coronavirus Vaccine Market Outlook, By Product Type (2017-2027) ($MN)
72 Europe Coronavirus Vaccine Market Outlook, By Monovalent Vaccine (2017-2027) ($MN)
73 Europe Coronavirus Vaccine Market Outlook, By Multivariant Vaccine (2017-2027) ($MN)
74 Europe Coronavirus Vaccine Market Outlook, By Route of Administration (2017-2027) ($MN)
75 Europe Coronavirus Vaccine Market Outlook, By Subcutaneous (2017-2027) ($MN)
76 Europe Coronavirus Vaccine Market Outlook, By Oral (2017-2027) ($MN)
77 Europe Coronavirus Vaccine Market Outlook, By Intramuscular (2017-2027) ($MN)
78 Europe Coronavirus Vaccine Market Outlook, By Patient Type (2017-2027) ($MN)
79 Europe Coronavirus Vaccine Market Outlook, By Pediatric (2017-2027) ($MN)
80 Europe Coronavirus Vaccine Market Outlook, By Adult (2017-2027) ($MN)
81 Europe Coronavirus Vaccine Market Outlook, By End User (2017-2027) ($MN)
82 Europe Coronavirus Vaccine Market Outlook, By Clinics (2017-2027) ($MN)
83 Europe Coronavirus Vaccine Market Outlook, By Hospitals (2017-2027) ($MN)
84 Europe Coronavirus Vaccine Market Outlook, By Research Institutes (2017-2027) ($MN)
85 Asia Pacific Coronavirus Vaccine Market Outlook, By Country (2017-2027) ($MN)
86 Asia Pacific Coronavirus Vaccine Market Outlook, By Infection Type (2017-2027) ($MN)
87 Asia Pacific Coronavirus Vaccine Market Outlook, By HCoV-229E (2017-2027) ($MN)
88 Asia Pacific Coronavirus Vaccine Market Outlook, By HCoV-OC43 (2017-2027) ($MN)
89 Asia Pacific Coronavirus Vaccine Market Outlook, By HKU1-CoV (2017-2027) ($MN)
90 Asia Pacific Coronavirus Vaccine Market Outlook, By MERS-CoV (2017-2027) ($MN)
91 Asia Pacific Coronavirus Vaccine Market Outlook, By New Haven CoV (2017-2027) ($MN)
92 Asia Pacific Coronavirus Vaccine Market Outlook, By SARS-CoV (2017-2027) ($MN)
93 Asia Pacific Coronavirus Vaccine Market Outlook, By Vaccine Type (2017-2027) ($MN)
94 Asia Pacific Coronavirus Vaccine Market Outlook, By S-Protein Based Coronavirus Vaccine (2017-2027) ($MN)
95 Asia Pacific Coronavirus Vaccine Market Outlook, By Live Attenuated Coronavirus Vaccine (2017-2027) ($MN)
96 Asia Pacific Coronavirus Vaccine Market Outlook, By Inactivated Coronavirus Vaccine (2017-2027) ($MN)
97 Asia Pacific Coronavirus Vaccine Market Outlook, By mRNA Vaccine (2017-2027) ($MN)
98 Asia Pacific Coronavirus Vaccine Market Outlook, By DNA-Based Vaccine (2017-2027) ($MN)
99 Asia Pacific Coronavirus Vaccine Market Outlook, By Product Type (2017-2027) ($MN)
100 Asia Pacific Coronavirus Vaccine Market Outlook, By Monovalent Vaccine (2017-2027) ($MN)
101 Asia Pacific Coronavirus Vaccine Market Outlook, By Multivariant Vaccine (2017-2027) ($MN)
102 Asia Pacific Coronavirus Vaccine Market Outlook, By Route of Administration (2017-2027) ($MN)
103 Asia Pacific Coronavirus Vaccine Market Outlook, By Subcutaneous (2017-2027) ($MN)
104 Asia Pacific Coronavirus Vaccine Market Outlook, By Oral (2017-2027) ($MN)
105 Asia Pacific Coronavirus Vaccine Market Outlook, By Intramuscular (2017-2027) ($MN)
106 Asia Pacific Coronavirus Vaccine Market Outlook, By Patient Type (2017-2027) ($MN)
107 Asia Pacific Coronavirus Vaccine Market Outlook, By Pediatric (2017-2027) ($MN)
108 Asia Pacific Coronavirus Vaccine Market Outlook, By Adult (2017-2027) ($MN)
109 Asia Pacific Coronavirus Vaccine Market Outlook, By End User (2017-2027) ($MN)
110 Asia Pacific Coronavirus Vaccine Market Outlook, By Clinics (2017-2027) ($MN)
111 Asia Pacific Coronavirus Vaccine Market Outlook, By Hospitals (2017-2027) ($MN)
112 Asia Pacific Coronavirus Vaccine Market Outlook, By Research Institutes (2017-2027) ($MN)
113 South America Coronavirus Vaccine Market Outlook, By Country (2017-2027) ($MN)
114 South America Coronavirus Vaccine Market Outlook, By Infection Type (2017-2027) ($MN)
115 South America Coronavirus Vaccine Market Outlook, By HCoV-229E (2017-2027) ($MN)
116 South America Coronavirus Vaccine Market Outlook, By HCoV-OC43 (2017-2027) ($MN)
117 South America Coronavirus Vaccine Market Outlook, By HKU1-CoV (2017-2027) ($MN)
118 South America Coronavirus Vaccine Market Outlook, By MERS-CoV (2017-2027) ($MN)
119 South America Coronavirus Vaccine Market Outlook, By New Haven CoV (2017-2027) ($MN)
120 South America Coronavirus Vaccine Market Outlook, By SARS-CoV (2017-2027) ($MN)
121 South America Coronavirus Vaccine Market Outlook, By Vaccine Type (2017-2027) ($MN)
122 South America Coronavirus Vaccine Market Outlook, By S-Protein Based Coronavirus Vaccine (2017-2027) ($MN)
123 South America Coronavirus Vaccine Market Outlook, By Live Attenuated Coronavirus Vaccine (2017-2027) ($MN)
124 South America Coronavirus Vaccine Market Outlook, By Inactivated Coronavirus Vaccine (2017-2027) ($MN)
125 South America Coronavirus Vaccine Market Outlook, By mRNA Vaccine (2017-2027) ($MN)
126 South America Coronavirus Vaccine Market Outlook, By DNA-Based Vaccine (2017-2027) ($MN)
127 South America Coronavirus Vaccine Market Outlook, By Product Type (2017-2027) ($MN)
128 South America Coronavirus Vaccine Market Outlook, By Monovalent Vaccine (2017-2027) ($MN)
129 South America Coronavirus Vaccine Market Outlook, By Multivariant Vaccine (2017-2027) ($MN)
130 South America Coronavirus Vaccine Market Outlook, By Route of Administration (2017-2027) ($MN)
131 South America Coronavirus Vaccine Market Outlook, By Subcutaneous (2017-2027) ($MN)
132 South America Coronavirus Vaccine Market Outlook, By Oral (2017-2027) ($MN)
133 South America Coronavirus Vaccine Market Outlook, By Intramuscular (2017-2027) ($MN)
134 South America Coronavirus Vaccine Market Outlook, By Patient Type (2017-2027) ($MN)
135 South America Coronavirus Vaccine Market Outlook, By Pediatric (2017-2027) ($MN)
136 South America Coronavirus Vaccine Market Outlook, By Adult (2017-2027) ($MN)
137 South America Coronavirus Vaccine Market Outlook, By End User (2017-2027) ($MN)
138 South America Coronavirus Vaccine Market Outlook, By Clinics (2017-2027) ($MN)
139 South America Coronavirus Vaccine Market Outlook, By Hospitals (2017-2027) ($MN)
140 South America Coronavirus Vaccine Market Outlook, By Research Institutes (2017-2027) ($MN)
141 Middle East & Africa Coronavirus Vaccine Market Outlook, By Country (2017-2027) ($MN)
142 Middle East & Africa Coronavirus Vaccine Market Outlook, By Infection Type (2017-2027) ($MN)
143 Middle East & Africa Coronavirus Vaccine Market Outlook, By HCoV-229E (2017-2027) ($MN)
144 Middle East & Africa Coronavirus Vaccine Market Outlook, By HCoV-OC43 (2017-2027) ($MN)
145 Middle East & Africa Coronavirus Vaccine Market Outlook, By HKU1-CoV (2017-2027) ($MN)
146 Middle East & Africa Coronavirus Vaccine Market Outlook, By MERS-CoV (2017-2027) ($MN)
147 Middle East & Africa Coronavirus Vaccine Market Outlook, By New Haven CoV (2017-2027) ($MN)
148 Middle East & Africa Coronavirus Vaccine Market Outlook, By SARS-CoV (2017-2027) ($MN)
149 Middle East & Africa Coronavirus Vaccine Market Outlook, By Vaccine Type (2017-2027) ($MN)
150 Middle East & Africa Coronavirus Vaccine Market Outlook, By S-Protein Based Coronavirus Vaccine (2017-2027) ($MN)
151 Middle East & Africa Coronavirus Vaccine Market Outlook, By Live Attenuated Coronavirus Vaccine (2017-2027) ($MN)
152 Middle East & Africa Coronavirus Vaccine Market Outlook, By Inactivated Coronavirus Vaccine (2017-2027) ($MN)
153 Middle East & Africa Coronavirus Vaccine Market Outlook, By mRNA Vaccine (2017-2027) ($MN)
154 Middle East & Africa Coronavirus Vaccine Market Outlook, By DNA-Based Vaccine (2017-2027) ($MN)
155 Middle East & Africa Coronavirus Vaccine Market Outlook, By Product Type (2017-2027) ($MN)
156 Middle East & Africa Coronavirus Vaccine Market Outlook, By Monovalent Vaccine (2017-2027) ($MN)
157 Middle East & Africa Coronavirus Vaccine Market Outlook, By Multivariant Vaccine (2017-2027) ($MN)
158 Middle East & Africa Coronavirus Vaccine Market Outlook, By Route of Administration (2017-2027) ($MN)
159 Middle East & Africa Coronavirus Vaccine Market Outlook, By Subcutaneous (2017-2027) ($MN)
160 Middle East & Africa Coronavirus Vaccine Market Outlook, By Oral (2017-2027) ($MN)
161 Middle East & Africa Coronavirus Vaccine Market Outlook, By Intramuscular (2017-2027) ($MN)
162 Middle East & Africa Coronavirus Vaccine Market Outlook, By Patient Type (2017-2027) ($MN)
163 Middle East & Africa Coronavirus Vaccine Market Outlook, By Pediatric (2017-2027) ($MN)
164 Middle East & Africa Coronavirus Vaccine Market Outlook, By Adult (2017-2027) ($MN)
165 Middle East & Africa Coronavirus Vaccine Market Outlook, By End User (2017-2027) ($MN)
166 Middle East & Africa Coronavirus Vaccine Market Outlook, By Clinics (2017-2027) ($MN)
167 Middle East & Africa Coronavirus Vaccine Market Outlook, By Hospitals (2017-2027) ($MN)
168 Middle East & Africa Coronavirus Vaccine Market Outlook, By Research Institutes (2017-2027) ($MN)
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
Select License Type
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.